Cargando…

Chaperone proteins as ameliorators of α-synuclein-induced synaptic pathologies: insights into Parkinson’s disease

Detalles Bibliográficos
Autores principales:	Banks, Susan M.L., Medeiros, Audrey T., Sousa, Rui, Lafer, Eileen M., Morgan, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224136/ https://www.ncbi.nlm.nih.gov/pubmed/33269774 http://dx.doi.org/10.4103/1673-5374.300431

Ejemplares similares

Hsc70 rescues the synaptic vesicle trafficking defects caused by α-synuclein dimers
por: Brady, Emily B., et al.
Publicado: (2023)

Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses
por: Banks, Susan M. L., et al.
Publicado: (2020)

Impacts of increased α-synuclein on clathrin-mediated endocytosis at synapses: implications for neurodegenerative diseases
por: Medeiros, Audrey T., et al.
Publicado: (2018)

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin
por: Kam, Tae-In, et al.
Publicado: (2022)

Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
por: Pozo Devoto, Victorio M., et al.
Publicado: (2017)

Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?
por: Zaltieri, Michela, et al.
Publicado: (2015)

Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease
por: Alvarez-Erviti, L, et al.
Publicado: (2013)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Effects of Excess Brain-Derived Human α-Synuclein on Synaptic Vesicle Trafficking
por: Román-Vendrell, Cristina, et al.
Publicado: (2021)

The role of molecular chaperones in clathrin mediated vesicular trafficking
por: Sousa, Rui, et al.
Publicado: (2015)

α-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling
por: Medeiros, Audrey T., et al.
Publicado: (2017)

Inducing α-synuclein compaction: a new strategy for inhibiting α-synuclein aggregation?
por: Pinheiro, Francisca, et al.
Publicado: (2019)

Functionally different α-synuclein inclusions yield insight into Parkinson’s disease pathology
por: Raiss, Christian C., et al.
Publicado: (2016)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

α-Synuclein-112 Impairs Synaptic Vesicle Recycling Consistent With Its Enhanced Membrane Binding Properties
por: Soll, Lindsey G., et al.
Publicado: (2020)

Myelin Pathology: Involvement of Molecular Chaperones and the Promise of Chaperonotherapy
por: Scalia, Federica, et al.
Publicado: (2019)

Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson’s disease-like pathology
por: Cao, Qianqian, et al.
Publicado: (2022)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
por: Tofaris, George K.
Publicado: (2022)

The Synaptic Function of α-Synuclein
por: Burré, Jacqueline
Publicado: (2015)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

α-Synuclein regulation by chaperones in mammalian cells
por: Burmann, Björn M., et al.
Publicado: (2019)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

The Janus face of N-terminal lysines in α-synuclein
por: Uceda, Ana Belén, et al.
Publicado: (2020)

Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
por: Wang, Rui, et al.
Publicado: (2022)

Small molecules to prevent the neurodegeneration caused by α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2020)

Impact of alpha-synuclein pathology on adult neurogenesis: evidence for multilayered mechanisms
por: Bonsberger, Jana, et al.
Publicado: (2021)

Retromer stabilization using a pharmacological chaperone protects in an α-synuclein based mouse model of Parkinson’s
por: Eleuteri, Simona, et al.
Publicado: (2023)

Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson’s disease
por: Phan, Jenny-Ann, et al.
Publicado: (2017)

Acute increase of α-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation
por: Busch, David J., et al.
Publicado: (2014)

Cellular response against cytosolic leakage of mitochondrial DNA: insights into the pathology of Parkinson’s disease
por: Sakai, Akiko, et al.
Publicado: (2022)

Alpha-synuclein as a biomarker in Parkinson's disease: focus on neural derived extracelluar vesicles
por: Agliardi, Cristina, et al.
Publicado: (2021)

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis
por: van den Berge, Simone A., et al.
Publicado: (2012)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease
por: Yang, Yunseon, et al.
Publicado: (2022)

Synaptic vesicle binding of α-synuclein is modulated by β- and γ-synucleins
por: Carnazza, Kathryn E., et al.
Publicado: (2022)

Cortical Synaptic Mechanism for Chronic Pain and Anxiety in Parkinson’s Disease
por: Zhou, Zhaoxiang, et al.
Publicado: (2023)

Beyond the SNARE: Munc18-1 chaperones α-synuclein
por: Deshpande, Mugdha, et al.
Publicado: (2016)

The unhappy chaperone
por: Linse, Sara, et al.
Publicado: (2021)

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
por: Rademacher, David J.
Publicado: (2023)

Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy
por: Chmielarz, Piotr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5upped4n62kuvd6g2couvkjl4r